Patient reported clinical outcomes and personal perspectives after risk reducing surgery von Kehoe, S.M, Mann, M, Richardson, D.L, Lea, J.S, Miller, D.S, Mauer, C

Volltext

GOG 186H: A randomized phase II evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin) in the treatment of recurrent or persistent ovarian, fal... von Cohn, D.E, Sill, M, Walker, J.L, O'Malley, D.M, Nagel, C.I, Rutledge, T, Bradley, W.H, Richardson, D.L, Moxley, K, Aghajanian, C

Volltext

Factors associated with clinical trial screening failures in gynecologic oncology von Paulsen, A, Richardson, D.L, Kehoe, S.M, Miller, D.S, Lea, J.S

Volltext

Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab? von Richardson, D.L, Backes, F.J, Hurt, J.D, Seamon, L.G, Copeland, L.J, Fowler, J.M, Cohn, D.E, O'Malley, D.M

Volltext

Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer von Hurt, J.D, Richardson, D.L, Seamon, L.G, Fowler, J.F, Copeland, L.J, Cohn, D.E, Eisenhauer, E, Salani, R, O'Malley, D.M

Volltext

Impact of circulating tumor cells (CTCs) on overall survival among patients treated with chemotherapy plus bevacizumab for advanced cervical cancer: An NRG Oncology/Gynecologic Onc... von Sill, M, Monk, B.J, Penson, R.T, Lankes, H, Leitao, M.M, Ramondetta, L.M, Van Le, L, Richardson, D.L, Landrum, L.M, DiSilvestro, P.A, Behbakht, K, Ueland, F.R, Michael, H, Birrer, M.J

Volltext

Light manipulation using organic semiconducting materials for enhanced photosynthesis von Zorz, Jackie, Richardson, William D.L., Laventure, Audrey, Haines, Marianne, Cieplechowicz, Edward, Aslani, Alireza, Vadlamani, Agasteswar, Bergerson, Joule, Welch, Gregory C., Strous, Marc

Volltext

Predictive value of carcinoembryonic antigen and cancer antigen 125 in identifying mucinous ovarian tumors von Manders, D.B, Purinton, S.C, Lea, J.S, Richardson, D.L, Miller, D.S, Kehoe, S.M

Volltext

Outcomes of third line chemotherapy for recurrent and persistent cervical cancer von Manders, D.B, Purinton, S.C, Lea, J.S, Miller, D.S, Kehoe, S.M, Richardson, D.L

Volltext

439TiP AVZO-021-1001: A first-in-human open-label, multicenter phase I/II dose-escalation and expansion study evaluating AVZO-021 in adult patients with advanced solid tumors von Dowlati, A., Richardson, D.L., Lorusso, P., Spira, A.I., Bashir, B., Hirmand, M., Mehta, M., Patel, M.R.

Volltext

Provider perspective on medical marijuana in oncology von Greenwood, A., Castellano, T., Richardson, D.L.

Volltext

Comparison of Image-Guided Intensity Modulated Radiotherapy (IG-IMRT) vs. Conventional Radiotherapy (4FRT) for Locoregionally Advanced Cervical Cancer on the NRG GY006 Trial von Mell, L.K., Deng, W., Gao, L., Kunos, C.M., Chino, J.P., Quick, A.M., Feddock, J.M., Donnelly, E.D., Albuquerque, K.V., Leif, J.L., Richardson, D.L., Amarnath, S.R., Jegadeesh, N., Santos-Reyes, L.J., MacKay, H., Aghajanian, C., Monk, B.J., Miller, A., Mayadev, J.S., Leath, C.

Volltext

691TiP PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation von Schram, A.M., Lopes, G., El-Khoueiry, A.B., Fontana, E., Karasic, T.B., Kummar, S., Lorusso, P., Gregorc, V., Millward, M., Ponce Aix, S., Richardson, D.L., Roda Perez, D., Spira, A.I., Tan, D.S., Thompson, J.A., Uprety, D., Fellous, M., Qin, Y.G., Dumbrava, E.E.

Volltext

719MO A phase I/II study of rinatabart sesutecan (Rina-S) in patients with advanced ovarian or endometrial cancer von Lee, E.K., Yeku, O., Winer, I., Hamilton, E.P., Richardson, D.L., Zhang, J., Konecny, G.E., Anderson, I.C., Wu, X., Orr, D., Patel, S., Jewell, A., Wang, J., Spira, A.I., Melnyk, A., Seamon, L., Kavalerchik, E., Chen, Z., Song, E., Call, J.A.

Volltext

921P HB-200 arenavirus-based immunotherapy plus pembrolizumab as a first-line treatment of patients with recurrent/metastatic HPV16 positive head and neck cancer von Nabell, L., Ho, A.L., Posner, M.R., Neupane, P., Naqash, A-R., Wong, S., Niu, J.J., Pearson, A.T., Laux, D., Adkins, D.R., Pimentel, A., Rosenberg, A.J., Richardson, D.L., Wong, W., Kaufmann, T.A., Katchar, K., Qing, X., Iacobucci, C., Schlienger, K., Pfister, D.

Volltext

A phase IB trial of paclitaxel and carboplatin + galunisertib in patients with uterine and ovarian carcinosarcoma von Gunderson, C.C., Walker, J.L., Mannel, R.S., Holman, L.L., Richardson, D.L., Ding, K., Moxley, K., Landrum, L.M., Rowland, M., Moore, K.N.

Volltext

VP2-2022: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced... von Vergote, I.B., Fidalgo, A. Pérez, Hamilton, E., Valabrega, G., Van Gorp, T., Sehouli, J., Cibula, D., Levy, T., Welch, S., Richardson, D.L., Alía, E.M. Guerra, Scambia, G., Henry, S., Wimberger, P., Miller, D., Martínez, J., Monk, B.J., Shacham, S., Mirza, M.R., Makker, V.

Volltext

Impact of financial assistance programs on time to completion of therapy in women receiving chemoradiation for cervical cancer von Gillen, J., Grimes, S., Essel, K.G., Duininck, G., Zhao, D., Thompson, J.S., Richardson, D.L.

Volltext

Controls on residence time and exchange in a system of shallow coastal bays von Safak, I., Wiberg, P.L., Richardson, D.L., Kurum, M.O.

Volltext

732P Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as a first-line treatment for endometrial cancer (EC): Progression-free survival (PFS) by clinical f... von Blank, S.V., McCollum, M., Anderson, C., Pennington, K., Salinas, E., Richardson, D.L., Slomovitz, B.M., Kim, B-G., Liu, J., Mori, M., Guette, P.L. Ramos, Joseph de Pádua, C., Martinez-Garcia, J., Papadimitriou, C., Grisan, K., Póka, R.L., Kowgier, M., Del Rosario, P.M.D., Van Nieuwenhuysen, E., Westin, S.

Volltext